Shortening the Ex Vivo Culture of CD19‐specific CAR T‐cells Retains Potent Efficacy Against Acute Lymphoblastic Leukemia Without CRES or Severe CRS

American Journal of Hematology - United States
doi 10.1002/ajh.25630